A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia

Journal of Pediatrics

Volumn 139, Issue 6, 2001, Pages 790-796

  Wang, Winfred C ^a,b,c,d,e   Wynn, Lynn W ^a,b,c,d,e   Rogers, Zora R ^a,b,c,d,e   Scott, J Paul ^a,b,c,d,e   Lane, Peter A ^a,b,c,d,e   Ware, Russell E ^a,b,c,d,e  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN S; HYDROXYUREA;

ARTICLE; ASPLENIA; BETA THALASSEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFANT; NEUTROPENIA; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SPLEEN FUNCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035666461     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2001.119590     Document Type: Article

References (31)

1. Levels of fetal hemoglobin necessary for treatment of sickle-cell disease
2. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle-cell anemia?
3. Pain in sickle-cell disease
4. Hydroxyurea as treatment for sickle-cell anemia
5. Effect of hydroxyurea on the frequency of painful crises in sickle-cell anemia
6. Safety of hydroxyurea in children with sickle-cell anemia: Results of the HUG-KIDS Study, a Phase I/II trial
7. Hydroxyurea therapy in children severely affected with sickle-cell disease
8. Hydroxyurea for treatment of severe sickle-cell anemia: A pediatric clinical trial
9. Clinical and hematologic effects of hydroxyurea in children with sickle-cell anemia
10. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle-cell disease
11. Use of hydroxyurea in children with sickle-cell disease: What comes next?
12. Hydroxyurea in children: Present and future
13. Hydroxyurea therapy for diverse pediatric populations with sickle-cell disease
14. Hydroxyurea in children with sickle-cell disease: Impact on splenic function and compliance with therapy
15. Functional asplenia in sickle-cell anemia
16. Infection caused by Streptococcus pneumoniae in children with sickle-cell disease: Epidemiology, immunologic mechanisms, prophylaxis, and vaccination
17. Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle-cell disease
18. Functional asplenia in hemoglobin SC disease
19. Reference values and hematologic changes from birth to 5 years in patients with sickle-cell disease
20. Longitudinal data analysis using generalized linear models
21. Abnormalities of the central nervous system in very young children with sickle-cell anemia
22. Adverse effects of hydroxyurea on growth and development of young mice
23. A cautionary note regarding hydroxyurea in sickle-cell disease
24. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle-cell disease
25. Physiologic decline in fetal hemoglobin parameters in infants with sickle-cell disease: Implications for pharmacological intervention
26. The acute chest syndrome in sickle-cell disease: Incidence and risk factors
27. Mortality in sickle-cell disease
28. Hydroxyurea and sickle-cell anemia: Clinical utility of a myelosuppressive "switching" agent
29. First report of reversal of organ dysfunction in sickle-cell anemia by the use of hydroxyurea: Splenic regeneration
30. Clinical events in the first decade in a cohort of infants with sickle-cell disease
31. Prediction of adverse outcomes in children with sickle-cell disease